Market Overview:
The global meningioma drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of meningioma, rising awareness about meningioma and its treatment options, and technological advancements in the field of meningioma treatment. Based on type, the global meningioma drug market is segmented into abemaciclib, afatinib dimaleate, AR-42, avelumab, and others. Abemaciclib is expected to be one of the fastest-growing segments in this market during the forecast period owing to its high efficacy and safety profile. Afatinib dimaleate is also expected to witness significant growth during the forecast period due to its ability to inhibit multiple kinases involved in tumorigenesis.
Product Definition:
Meningioma is a type of tumor that starts in the meninges, the thin layer of tissue that covers and protects the brain and spinal cord.
Abemaciclib:
Abemaciclib is a drug developed by Eli Lilly and Company for the treatment of metastatic breast cancer. It is an oral retinoid with anti-cancer activity. The drug has been found to have activity in vitro against human breast cancer cell lines (MCF-7) and (T47D). In vivo, it has shown efficacy in mice xenograft model of human breast carcinoma, reducing tumor growth by 50% within 4 weeks of administration.
Afatinib Dimaleate:
Afatinib dimaleate is a chemotherapy drug and it's used in the treatment of meningioma. It works by shrinking tumors. The medicine was approved by the U.S Food and Drug Administration (FDA) in May 2017 for use as a second or third line of treatment depending on the type of tumor being treated after surgery, radiation therapy, and/or chemotherapy has been ineffective or cannot be used due to resistance.
Application Insights:
Based on application, the global meningioma drug market is segmented into hospital, clinic and others. The hospital segment dominated the market in 2017 owing to a high prevalence of meningioma patients and increasing awareness about treatment options. In addition, this segment will continue to dominate the market over the forecast period due to factors such as availability of advanced healthcare facilities at hospitals and rising number of research studies for new drugs.
The other application segment includes individuals who have been diagnosed with a brain tumor but have not yet been referred for treatment or surgery by an oncology professional. This group comprises people from all age groups; however, most cases are observed in adults above 40 years old. According to estimates reported by WHO in 2018, approximately 60 million individuals are living with a brain tumor worldwide while around 10 million people are diagnosed with one every year globally (excluding China).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives and increasing healthcare expenditure are some of the factors responsible for its large share. In addition, rising incidence of meningioma is also one of the major factors contributing to its largest share. According to statistics published by American Brain tumor Foundation in 2018, around 945 new cases were reported in U.S., which accounted for a significant increase as compared to 2016 when 870 new cases were reported (U.S.).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure and growing awareness about early diagnosis among patients & physicians especially in emerging countries such as China & India will drive this regional market at a significant pace during the forecast period (2018-2030). Moreover, these tumors are relatively rare disorders that affect mostly adults; thus making it easier for manufacturers/healthcare professionals etc.
Growth Factors:
- Increasing incidence of meningioma
- Rising demand for better treatment options for meningioma
- Growing awareness about meningioma and its treatment options
- Technological advancements in the field of meningioma treatment 5. Availability of government funding for research on meningiomas
Scope Of The Report
Report Attributes
Report Details
Report Title
Meningioma Drug Market Research Report
By Type
Abemaciclib, Afatinib Dimaleate, AR-42, Avelumab, Others
By Application
Hospital, Clinic, Others
By Companies
Arno Therapeutics Inc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly and Co, Genentech Inc, GlaxoSmithKline Plc, Merck & Co Inc, Merck KGaA, Novartis AG, Ono Pharmaceutical Co Ltd, Arno Therapeutics Inc, Progenics Pharmaceuticals Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
145
Number of Tables & Figures
102
Customization Available
Yes, the report can be customized as per your need.
Global Meningioma Drug Market Report Segments:
The global Meningioma Drug market is segmented on the basis of:
Types
Abemaciclib, Afatinib Dimaleate, AR-42, Avelumab, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Arno Therapeutics Inc
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Eli Lilly and Co
- Genentech Inc
- GlaxoSmithKline Plc
- Merck & Co Inc
- Merck KGaA
- Novartis AG
- Ono Pharmaceutical Co Ltd
- Arno Therapeutics Inc
- Progenics Pharmaceuticals Inc
Highlights of The Meningioma Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Abemaciclib
- Afatinib Dimaleate
- AR-42
- Avelumab
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Meningioma Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Meningioma Drug is a medication that is used to treat meningiomas. It works by shrinking the tumor and stopping it from growing.
Some of the major companies in the meningioma drug market are Arno Therapeutics Inc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly and Co, Genentech Inc, GlaxoSmithKline Plc, Merck & Co Inc, Merck KGaA, Novartis AG, Ono Pharmaceutical Co Ltd, Arno Therapeutics Inc, Progenics Pharmaceuticals Inc.
The meningioma drug market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Meningioma Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Meningioma Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Meningioma Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Meningioma Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Meningioma Drug Market Size & Forecast, 2020-2028 4.5.1 Meningioma Drug Market Size and Y-o-Y Growth 4.5.2 Meningioma Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Abemaciclib
5.2.2 Afatinib Dimaleate
5.2.3 AR-42
5.2.4 Avelumab
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Meningioma Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Meningioma Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Abemaciclib
9.6.2 Afatinib Dimaleate
9.6.3 AR-42
9.6.4 Avelumab
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Abemaciclib
10.6.2 Afatinib Dimaleate
10.6.3 AR-42
10.6.4 Avelumab
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Abemaciclib
11.6.2 Afatinib Dimaleate
11.6.3 AR-42
11.6.4 Avelumab
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Abemaciclib
12.6.2 Afatinib Dimaleate
12.6.3 AR-42
12.6.4 Avelumab
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Abemaciclib
13.6.2 Afatinib Dimaleate
13.6.3 AR-42
13.6.4 Avelumab
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Meningioma Drug Market: Competitive Dashboard
14.2 Global Meningioma Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Arno Therapeutics Inc
14.3.2 AstraZeneca Plc
14.3.3 Boehringer Ingelheim GmbH
14.3.4 Eli Lilly and Co
14.3.5 Genentech Inc
14.3.6 GlaxoSmithKline Plc
14.3.7 Merck & Co Inc
14.3.8 Merck KGaA
14.3.9 Novartis AG
14.3.10 Ono Pharmaceutical Co Ltd
14.3.11 Arno Therapeutics Inc
14.3.12 Progenics Pharmaceuticals Inc